electroCore Study Shows Non-Invasive Vagus Nerve Stimulation Benefits for mTBI and PTSD Patients

Event summary

  • electroCore published a study in Frontiers in Neuroscience on April 1, 2026, showing adjunctive non-invasive vagus nerve stimulation (nVNS) reduced symptom burden in 35 patients with chronic mild traumatic brain injury (mTBI) and PTSD.
  • The study demonstrated improvements across cognitive, affective, and somatic domains in high-symptom-burden patients.
  • electroCore's gammaCore nVNS device is currently approved for primary headache conditions and fibromyalgia symptoms.
  • The company is exploring regulatory clearances for additional indications, including mTBI and PTSD.

The big picture

electroCore's study adds to the growing evidence supporting nVNS in neuropsychiatric conditions, positioning the company to potentially expand into high-need areas like mTBI and PTSD. The findings could drive regulatory and commercial opportunities, though success will depend on further clinical validation and market adoption. The broader trend of bioelectronic medicine gaining traction in mental health underscores the strategic significance of this development.

What we're watching

Regulatory Pathway
Whether electroCore can secure regulatory approvals for nVNS in mTBI and PTSD, expanding its market potential.
Clinical Validation
The pace at which additional clinical evidence supports nVNS's efficacy in neuropsychiatric conditions.
Market Expansion
How electroCore leverages this data to penetrate new therapeutic areas beyond headaches and fibromyalgia.